Psoriasis, Quality of Life
Conditions
Brief summary
This work aimed to study some epidemiological features and the clinical profile of patients having psoriasis visiting the Dermatology and Venereology departments of Tanta University Hospitals and to assess the impact of disease on their quality of life.
Detailed description
Psoriasis is a genetically determined, systemic immune-mediated inflammatory disease that affects predominantly the skin and joints. It is now recognized as a systemic disease, which is associated with multiple comorbidities, including diabetes, hypertension, obesity, and major cardiovascular adverse events. These can shorten the lifespan of patients with severe disease by up to 5 years. The presentation of psoriasis varies from dusky red scaly papules to raised plaques on the elbows, knees, or scalp to superficial pustules dispersed on the palms or soles or, in rare cases, widespread pustules all over the body. The plaque, guttate, small plaque, inverse, erythrodermic, and pustular forms of psoriasis are among the clinical spectrum's variants. Psoriasis can be diagnosed clinically. However, a skin biopsy may be required for cases in which the presentation is not typical.
Interventions
OTHERQuality of Life assessment
Patients completed the Dermatology Life Quality Index (DLQI), which includes 10 questions and is designed for use in adults. Each question is scored on a 4-point scale from 0 ("Not at all") to 3 ("Very much") to assess the past seven days, providing a total score ranging from 0 to 30: 0 - 1: No effect at all on patient's life. 2 - 5: Small effect on patient's life. 6 - 10: Moderate effect on patient's life. 11 - 20: Very large effect on patient's life. 21 - 30: Extremely large effect on patient's life.
Sponsors
Tanta University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Psoriatic patients of both genders aged ≥18 years old. * Patients accepted to be enrolled in this study.
Exclusion criteria
\- Patients below 18 years old.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dermatology Life Quality Index (DLQI) | Six months after the survey. | Patients completed the Dermatology Life Quality Index (DLQI), which includes 10 questions and is designed for use in adults. Each question is scored on a 4-point scale from 0 ("Not at all") to 3 ("Very much") to assess the past seven days, providing a total score ranging from 0 to 30: 0 - 1: No effect at all on patient's life. 2 - 5: Small effect on patient's life. 6 - 10: Moderate effect on patient's life. 11 - 20: Very large effect on patient's life. 21 - 30: Extremely large effect on patient's life. |
Countries
Egypt
Outcome results
None listed